New combo therapy for AML enters early human testing

NCT ID NCT04150887

Ongoing Disease control Sponsor: OncoVerity, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug called cusatuzumab alongside usual treatments for adults with acute myeloid leukemia (AML) who cannot have intensive chemotherapy. The main goal is to check the safety and side effects of the combination. About 61 participants will receive the drug, and researchers will also measure how the body processes it and whether it helps control the leukemia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA, MYELOID, ACUTE

Contacts and locations

Locations

Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
City of Hope

Duarte, California, 91010, United States
INSELSPITAL, Universitätsspital Bern

Bern, 3010, Switzerland
Instytut Hematologii i Transfuzjologii

Warsaw, 02-776, Poland
Kantonsspital St.Gallen

Sankt Gallen, 9007, Switzerland
Klinikum der Universitaet Muenchen

München, 81377, Germany
McGill University Health Centre

Montreal, Quebec, H4A 3J1, Canada
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Norton Cancer Institute

Louisville, Kentucky, 40207, United States
Roswell Park Cancer Institute

Buffalo, New York, 14203, United States
Szpital Uniwersytecki w Krakowie

Krakow, 31-501, Poland
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
Tom Baker Cancer Centre

Calgary, Alberta, T2N 4N2, Canada
Universitaetsklinik Hamburg-Eppendorf

Hamburg, 20246, Germany
Universitaetsklinikum Leipzig

Leipzig, 04103, Germany
University of Alberta Hospital

Edmonton, Alberta, T6G 2B7, Canada
University of Pittsburgh School of Medicine

Pittsburgh, Pennsylvania, 15232, United States
University of Rochester

Rochester, New York, 14642, United States
University of Toronto

Toronto, Ontario, M5G 2M9, Canada
University of Vermont

Burlington, Vermont, 05401, United States
Weill Cornell Medicine

New York, New York, 10021, United States
Wisconsin Medical Center

Milwaukee, Wisconsin, 53226, United States
Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi

Lodz, 93-513, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.